文献速递中药与中成药合理使用

国际多中心临床试验在中药领域的现状与展望

Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine.
PubMed 文献 · Front Pharmacol · 2023-05-18

本文综述了中药(TCHM)国际多中心临床试验的现状,指出中国中药研究质量提升、国际化加速,约10个产品向美国FDA提交IND申请,复方丹参滴丸、杏灵颗粒、HMPL-004等进入III期临床。但真正国际多中心试验仍罕见,近十年SCI文献数总体增加,近两年因COVID-19疫情明显减少。

要点

  • 中药国际多中心临床试验数量逐年增加,但真正国际多中心试验仍罕见。
  • 约10个中药产品向美国FDA提交IND申请,多个品种进入III期临床。
  • 近十年中药多中心临床试验SCI文献数总体增加,近两年因COVID-19疫情减少。

核心结论

  • 高质量多中心临床试验仍是中药进入主流医药市场的关键途径。
  • 需进一步完善既符合国际标准又体现中药特点的评价技术与方法。

研究设计与样本

  • 本文为综述,检索范围未在摘要中明确报告。

主要发现

  • 约10个中药产品向美国FDA提交IND申请,复方丹参滴丸、杏灵颗粒、HMPL-004等获批开展III期临床试验。
  • 由中国大陆与其他海外地区开展的中药多中心临床试验中,近70%聚焦经典方剂与中成药,其余30%为膳食补充剂与植物提取物。
  • 近十年中药多中心临床试验SCI文献数总体呈增加趋势,但近两年因COVID-19疫情明显减少。

临床怎么用

  • 应有效利用中药历史「人用经验」以激活原创科技资源潜力。
  • 开展高质量国际多中心临床试验是中药进入主流医药市场的重要方法。
  • 需关注中药特定临床价值与科学报告。

局限性

  • 摘要未报告具体检索范围、样本量或偏倚控制方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the introduction of various subjects, such as clinical epidemiology and evidence-based medicine, the qualities and levels of Traditional Chinese Herbal Medicine (TCHM) in China improved substantially, and the processes of internationalization of Traditional Chinese Medicine (TCM) are further accelerated. Since, a variety of drug products in China have been approved for marketing in other countries, and approximately 10 products have submitted the IND application to FDA of United States, of which various Chinese herbal preparations such as compound Danshen dripping pills, Xingling granules, and HMPL-004 have been approved to be investigated in phase III clinical trials. In general, multi-center studies of TCHM are increasing with years, but most of the studies are performed in some certain country, and the actual international multi-center clinical trials are very rare. Number of SCI literatures on multi-center clinical trials of TCHM that published in the recent decade also showed increasing tendency with years, despite the evident reduction in the past 2 years due to the influence of COVID-19 pandemic. Of the multi-center clinical trials of TCHM that performed by mainland China and other oversees regions, except for Taiwan, China, nearly 70% were focused on classic Chinese medicinal formulae and Chinese patent medicine, while the other 30% were on dietary supplements and plant extracts. Facing the future, the "human experience" has attracted close attentions from researchers throughout the world. Effectively utilizing the historic "human experience" is an important method to vitalize potential of original scientific and technological resources of TCHM. Performing multi-center clinical trials with high qualities is still an essential method for TCHM in accessing the mainstream medicine market. In addition, it is also required to further improve the evaluation techniques and methods that not only meet the international standards but also meet the characteristics of TCHM. Furthermore, we should also focus on the TCHM specific clinical values and scientific reports.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wu S, Wang C, Bai D, et al. Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine. Front Pharmacol. 2023. PMID: 37274102. doi:10.3389/fphar.2023.1195364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。